United states securities and exchange commission

Table of Contents
18
Spinal Muscular Atrophy
SPINRAZA is the only approved treatment for 
SMA. We are aware of other products in development 
that, if successfully developed and approved, may 
compete with SPINRAZA in the SMA market. 
Psoriasis
FUMADERM competes with several different 
types of therapies in the psoriasis market within 
Germany, including oral systemics such as 
methotrexate and cyclosporine.
Biosimilars
BENEPALI and FLIXABI, the two biosimilars we 
currently manufacture and commercialize in the E.U. 
for Samsung Bioepis, compete with their applicable 
reference products, ENBREL and REMICADE, 
respectively, as well as other biosimilars of those 
reference products. 
Genentech Relationships in Other Indications
RITUXAN and GAZYVA in Oncology
RITUXAN and GAZYVA compete with a number of 
therapies in the oncology market, including TREANDA 
(bendamustine HCL), ARZERRA (ofatumumab), 
IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). 
We also expect that over time GAZYVA will 
increasingly compete with RITUXAN in the oncology 
market. In addition, we are aware of other anti-CD20 
molecules, including biosimilars, in development that, 
if successfully developed and approved, may compete 
with RITUXAN and GAZYVA in the oncology market.
RITUXAN in Rheumatoid Arthritis
RITUXAN competes with several different types 
of therapies in the rheumatoid arthritis market, 
including, among others, traditional disease-modifying 
anti-rheumatic drugs such as steroids, methotrexate 
and cyclosporine, TNF inhibitors, ORENCIA 
(abatacept), ACTEMRA (tocilizumab) and XELJANZ 
(tofacitinib).
We are also aware of other products, including 
biosimilars, in development that, if successfully 
developed and approved, may compete with RITUXAN 
in the rheumatoid arthritis market. 
Research and Development Programs
A commitment to research is fundamental to our 
mission. Our research efforts are focused on better 
understanding the underlying biology of diseases so 
we can discover and deliver treatments that have the 
potential to make a real difference in the lives of 
patients with high unmet medical needs. By applying 
our expertise in biologics and our growing capabilities 
in small molecule, antisense, gene therapy, gene 
editing and other technologies, we target specific 
medical needs where we believe new or better 
treatments are needed.
We intend to continue committing significant 
resources to research and development opportunities.  
As part of our ongoing research and development 
efforts, we have devoted significant resources to 
conducting clinical studies to advance the 
development of new pharmaceutical products and 
technologies and to explore the utility of our existing 
products in treating disorders beyond those currently 
approved in their labels.

---

Table of Contents
19
The table below highlights our current research and development programs that are in clinical trials and the 
current phase of such programs. Drug development involves a high degree of risk and investment, and the status, 
timing and scope of our development programs are subject to change. Important factors that could adversely affect 
our drug development efforts are discussed in Item 1A. Risk Factors included in this report. 
Core
Growth
Areas
MS and Neuroimmunology
BIIB098 (monomethly fumarate prodrug)* - MS
Phase 3
Opicinumab (anti-LINGO-1) - MS
Phase 2
Alzheimer's Disease and Dementia
Phase 3
Elenbecestat (E2609)* - Alzheimer's
Phase 3
Phase 2
BIIB092 (anti-tau mAb) - Alzheimer's
Phase 1
BIIB076 (anti-tau mAb)* - Alzheimer's
Phase 1
BIIB080 (IONIS-MAPT
Rx
)* - Alzheimer's
Phase 1
Parkinson's Disease and Movement Disorders
BIIB092 (anti-tau mAb) - PSP
Phase 2
BIIB054 (anti-
alpha
-synuclein mAb) - Parkinson's
Phase 2
Neuromuscular Disease Including SMA and ALS
BIIB067 (IONIS-SOD1
Rx
)* - ALS
Phase 1
Emerging
Growth
Areas
Pain
BIIB074 (Vixotrigine) - Trigeminal Neuralgia
Phase 2
BIIB074 (Nav1.7) - PLSR
#
Phase 2
Ophthalmology
BIIB087 (gene therapy)* - XLRS^
Phase 1/2
Acute Neurology
BIIB093 (glibenclamide IV) - LHI Stroke
Phase 2
Natalizumab - AI Stroke
Phase 2
Natalizumab - Epilepsy
Phase 2
Other
Dapirolzumab pegol (anti-CD40L)* - SLE
@
Phase 2
BG00011 (STX-100) - IPF
Phase 2
BIIB059 (anti-BDCA2) - SLE
@
Phase 2
* Collaboration programs
# Painful Lumbosacral Radiculophath (PLSR)
^ X-linked Retinoschisis (XLRS)
@ Systemic Lupus Erythematosus (SLE)
For information about certain of our agreements with collaborators and other third parties, please read the 
subsection entitled “Business Relationships” below and Note 20, Collaborative and Other Relationships, to our 
consolidated financial statements included in this report.
Business Relationships
As part of our business strategy, we establish 
business relationships, including joint ventures and 
collaborative arrangements with other companies, 
universities and medical research institutions, to 
assist in the clinical development and/or 
commercialization of certain of our products and 
product candidates and to provide support for our 
research programs. We also evaluate opportunities for 
acquiring products or rights to products and 
technologies that are complementary to our business 
from other companies, universities and medical 
research institutions.
Below is a brief description of certain business 
relationships and collaborations that expand our 
pipeline and provide us with certain rights to existing 
and potential new products and technologies. For 
additional information on certain of these 
relationships, including their ongoing financial and 
accounting impact on our business, please read Note 
19, Investments in Variable Interest Entities, and Note 
20, Collaborative and Other Relationships, to our 
consolidated financial statements included in this 
report.

---